The Network Pharmacology Company
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.
e-Therapeutics is listed on AIM with the ticker symbol ETX
Progress in ETS2101 ph1a and oral dosing studies
e-Therapeutics reports progress in ETS2101 phase 1a and oral dosing studies, The full press release can be read here.
Research and Development Presentation
e-Therapeutics held a Research and Development presentation for investors and analysts on 27 November.
More details available here.
Update on ETS2101 phase I trial in brain cancerNo serious drug-related adverse events after five dose escalation steps; patients to be enrolled at higher dose levels.
The full press release can be read here.
The impact of e-Therapeutics plc (AIM: ETX) drug discovery activities has been rated World Class by the UK's National Research and Impact Assessment exercise. More details available here.